Skip to main content
. 2019 Nov 13;3(11):e10233. doi: 10.1002/jbm4.10233

Figure 2.

Figure 2

ICER = incremental cost‐effectiveness ratio ($/quality‐adjusted life year). The results of deterministic sensitivity analyses around the costs of teriparatide. The estimated costs of generic/biosimilar teriparatide were decreased in 5% increments compared with the base case assumptions (ie, 70% of brand product). The estimated annual costs of teriparatide were calculated based on the assumption that 90% took generic/biosimilar and 10% took brand products.